← Leaderboards
Gary K Schwartz
Columbia University Health Sciences
$24,362,901
Attributed
$31,337,158
Total exposure
21
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.5M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$45,969,513 · 20
FDA$2,636,349 · 2
By mechanism
P30$21,127,814 · 7
R01$10,249,020 · 4
UG1$6,785,447 · 1
K12$3,023,244 · 2
T32$1,563,342 · 1
R38$1,432,080 · 1
Top collaborators
- Andrew B Lassman8 shared
- Alfred I Neugut8 shared
- Dawn Hershman5 shared
- Katherine D Crew4 shared
- Gulam Abbas Manji4 shared
- Stephen G Emerson1 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Anil K Rustgi$51,275,906
- Timothy Cragin Wang$52,188,834
- Cory Abate-Shen$42,493,197
- Tom K Hei$15,845,970
- Howard B Lieberman$13,315,678
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsClinical ResearchProgramsMalignant NeoplasmsResponseFutureResearch PersonnelInstitutionBaseUniversitiesTrainingPathway InteractionsGrantPreventionTumorPharmaceutical PreparationsResourcesAnticancer ResearchDesignAwardTraining ProgramsCancer CareFundingNeoplasm /Cancer Chemotherapy
Grant awards (75)
Case Comprehensive Cancer Center Support Grant$5,673,191
P30 · FY2025 · CA · contact PI
Leadership, Planning, and Evaluation$665,165
P30 · FY2025 · CA · contact PI
Developmental Funds$429,339
P30 · FY2025 · CA · contact PI
Clinical Oncology Research Program (CORP)$54,000
K12 · FY2025 · CA · contact PI
Case Comprehensive Cancer Center Support Grant$5,673,191
P30 · FY2024 · CA · contact PI
Leadership, Planning, and Evaluation$782,071
P30 · FY2024 · CA · contact PI
Developmental Funds$600,232
P30 · FY2024 · CA · contact PI
Case Comprehensive Cancer Center Support Grant$249,131
P30 · FY2024 · CA · contact PI
Case Comprehensive Cancer Center Support Grant$5,673,191
P30 · FY2023 · CA · contact PI
Leadership, Planning, and Evaluation$782,071
P30 · FY2023 · CA · contact PI
Developmental Funds$600,232
P30 · FY2023 · CA · contact PI
Phase 2 study of combination therapy with PLX3397 and sirolimus to target tumor-associated macrophages in malignant peripheral nerve sheath tumors$405,830
R01 · FY2023 · FD
Columbia University Minority/Underserved Site NCI Community Oncology Research Program$1,021,013
UG1 · FY2021 · CA · contact PI
Phase 2 study of combination therapy with PLX3397 and sirolimus to target tumor-associated macrophages in malignant peripheral nerve sheath tumors$500,000
R01 · FY2021 · FD
Molecular Oncology Training Program$445,219
T32 · FY2021 · CA · contact PI
CAPRI: Columbia Cancer Training Program for Resident-Investigators$358,020
R38 · FY2021 · CA
Columbia University Minority/Underserved Site NCI Community Oncology Research Program$937,767
UG1 · FY2020 · CA · contact PI
Phase 2 study of combination therapy with PLX3397 and sirolimus to target tumor-associated macrophages in malignant peripheral nerve sheath tumors$500,000
R01 · FY2020 · FD
CAPRI: Columbia Cancer Training Program for Resident-Investigators$358,020
R38 · FY2020 · CA
Molecular Oncology Training Program$354,428
T32 · FY2020 · CA · contact PI
Columbia University Minority/Underserved Site NCI Community Oncology Research Program$162,000
UG1 · FY2020 · CA · contact PI
Columbia University Minority/Underserved Site NCI Community Oncology Research Program$899,704
UG1 · FY2019 · CA · contact PI
CAPRI: Columbia Cancer Training Program for Resident-Investigators$358,020
R38 · FY2019 · CA
Molecular Oncology Training Program$284,477
T32 · FY2019 · CA · contact PI
Columbia University Minority/Underserved Site NCI Community Oncology Research Program$1,045,994
UG1 · FY2018 · CA · contact PI
CAPRI: Columbia Cancer Training Program for Resident-Investigators$358,020
R38 · FY2018 · CA
Molecular Oncology Training Program$247,594
T32 · FY2018 · CA · contact PI
Columbia University Minority/Underserved Site NCI Community Oncology Research Program$993,969
UG1 · FY2017 · CA · contact PI
Phase 2 study of combination therapy with PLX3397 and sirolimus to target tumor-associated macrophages in malignant peripheral nerve sheath tumors$500,000
R01 · FY2017 · FD
Molecular Oncology Training Program$160,153
T32 · FY2017 · CA · contact PI
Columbia University Minority/Underserved Site NCI Community Oncology Research Program$1,070,000
UG1 · FY2016 · CA · contact PI
Molecular Oncology Training Program$71,471
T32 · FY2016 · CA
Columbia University Minority/Underserved Site NCI Community Oncology Research Program$655,000
UG1 · FY2015 · CA · contact PI
P2 - Developing New Strategies for Targeting PDGFR/PI3K/AKT Pathways in Sarcoma$202,324
P50 · FY2014 · CA · contact PI
P2 - Developing New Strategies for Targeting PDGFR/PI3K/AKT Pathways in Sarcoma$202,094
P50 · FY2013 · CA · contact PI
Developing New Strategies for Targeting mTOR and IGF-1R/PI3K/Akt Pathways in Sarc$382,245
R01 · FY2012 · CA · contact PI
Developing New Strategies for Targeting mTOR and IGF-1R/PI3K/Akt Pathways in Sarc$327,405
R01 · FY2012 · CA · contact PI
P2 - Developing New Strategies for Targeting PDGFR/PI3K/AKT Pathways in Sarcoma$217,269
P50 · FY2012 · CA · contact PI
Developing New Strategies for Targeting mTOR and IGF-1R/PI3K/Akt Pathways in Sarc$728,428
R01 · FY2011 · CA · contact PI
P2 - Developing New Strategies for Targeting PDGFR/PI3K/AKT Pathways in Sarcoma$207,496
P50 · FY2011 · CA · contact PI
Translational Research Studies in Clinical Trials of Novel Therapeutics for Sarco$1,184,449
RC2 · FY2010 · CA · contact PI
Developing New Strategies for Targeting mTOR and IGF-1R/PI3K/Akt Pathways in Sarc$758,011
R01 · FY2010 · CA · contact PI
MSKCC Clinical Oncology Research Career Development Program$663,678
K12 · FY2010 · CA · contact PI
Laboratory & Clinical Develpmt of Cell Cycle Active Agents in the Treatmt of STS$229,171
P01 · FY2010 · CA · contact PI
Phase II Study of Imatinib Mesylate in Patients with Inoperable Melanoma$228,114
R01 · FY2010 · FD · contact PI
P2 - Developing New Strategies for Targeting PDGFR/PI3K/AKT Pathways in Sarcoma$220,918
P50 · FY2010 · CA · contact PI
Developing New Strategies for Targeting mTOR and IGF-1R/PI3K/Akt Pathways in Sarc$736,338
R01 · FY2009 · CA · contact PI
MSKCC Clinical Oncology Research Career Development Program$641,691
K12 · FY2009 · CA · contact PI
Phase II Study of Imatinib Mesylate in Patients with Inoperable Melanoma$239,650
R01 · FY2009 · FD · contact PI
Laboratory & Clinical Develpmt of Cell Cycle Active Agents in the Treatmt of STS$226,189
P01 · FY2009 · CA · contact PI
Clinical Trials of Flavopiridol with Chemotherapy$679,347
R01 · FY2008 · CA · contact PI
Phase II Study of Imatinib Mesylate in Patients with Inoperable Melanoma$262,755
R01 · FY2008 · FD · contact PI
Laboratory & Clinical Develpmt of Cell Cycle Active Agents in the Treatmt of STS$221,108
P01 · FY2008 · CA · contact PI
MSKCC Clinical Oncology Research Career Development Program$59,453
K12 · FY2008 · CA · contact PI
MSKCC Clinical Oncology Research Career Development Program$809,438
K12 · FY2007 · CA · contact PI
Clinical Trials of Flavopiridol with Chemotherapy$685,940
R01 · FY2007 · CA · contact PI
Laboratory & Clinical Develpmt of Cell Cycle Active Agents in the Treatmt of STS$220,453
P01 · FY2007 · CA · contact PI
MSKCC Clinical Oncology Research Career Development Program$794,984
K12 · FY2006 · CA · contact PI
Clinical Trials of Flavopiridol with Chemotherapy$601,307
R01 · FY2006 · CA · contact PI
Phase I Trial of Safingol and Cisplatin$258,276
R21 · FY2006 · CA · contact PI
Laboratory & Clinical Develpmt of Cell Cycle Active Agents in the Treatmt of STS$98,991
P01 · FY2006 · CA · contact PI
Clinical Trials of Flavopiridol with Chemotherapy$615,617
R01 · FY2005 · CA
Phase I Trial of Safingol and Cisplatin$264,492
R21 · FY2005 · CA
MENTORING FOR NEW CANCER THERAPEAUTICS$135,161
K24 · FY2005 · CA
GENETICS OF LOW RENIN HYPERTENSION$34,120
M01 · FY2005 · RR
Clinical Trials of Flavopiridol with Chemotherapy$597,983
R01 · FY2004 · CA
MENTORING FOR NEW CANCER THERAPEAUTICS$131,223
K24 · FY2004 · CA
CLINICAL TRIALS OF FLAVOPIRIDOL WITH CHEMOTHERAPY$548,956
R01 · FY2003 · CA
MENTORING FOR NEW CANCER THERAPEAUTICS$127,402
K24 · FY2003 · CA
CLINICAL TRIALS OF FLAVOPIRIDOL WITH CHEMOTHERAPY$346,410
R01 · FY2002 · CA
Drg1: A Novel Molecular Target for Cancer Therapy$193,563
R01 · FY2002 · CA
MENTORING FOR NEW CANCER THERAPEAUTICS$123,691
K24 · FY2002 · CA
CLINICAL TRIALS OF FLAVOPIRIDOL WITH CHEMOTHERAPY$337,690
R01 · FY2001 · CA
MENTORING FOR NEW CANCER THERAPEAUTICS$120,088
K24 · FY2001 · CA
PROTEIN KINASE C--A NOVEL TARGET FOR CANCER THERAPY$73,431
R01 · FY2000 · CA